To request a Grand Rounds CLICK HERE

Would you like to host a complimentary Grand Rounds presentation for your hematologists, oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and all other allied health professionals of the hematology/oncology team. This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.

Learning Objectives
•Outline the role of the B-cell receptor (BCR) pathway in the development of B-cell malignancies and identify enzymes downstream of the BCR that can serve as therapeutic agents.  
•Examine recent, top-line trial data for novel agents in the treatment of B-cell malignancies, including, BTK inhibitors, PI3K inhibitors, and BCL2 inhibitors.
•Analyze the most recent national guideline recommendations for the treatment of various B-cell malignancies and discuss the emerging role of novel agents into these treatment paradigms.
•Using a case-based approach, assess key issues in therapy selection, optimizing the use of novel therapies, managing adverse events, increasing patient adherence, and improving communication with both patients and with other members of the oncology care team.

5 min -  Welcome and Introductions
10 min - The BCR Pathway: A Key Target in B-cell Malignancies 
25 min - Exploring Contemporary Treatment Approaches: Novel Agents in B-cell Malignancies 
15 min - Putting it into Practice: Patient Cases and Practical Strategies for Interprofessional Oncology Care Team
5 min -  Conclusion and Q&A

Matthew S. Davids, MD
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA

This program has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Creative Educational Concepts. The University of Cincinnati is accredited by the ACCME to provide continuing education for physicians. 

Medicine (ACCME)
The University of Cincinnati designates this live activity for a maximum of 1 AMA PRA Category Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-9999-21-008-L01-P)

Nursing (ANCC)
This activity is designated for 1.0 contact hour. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Supported by independent educational grants from Janssen and AstraZeneca.